Impact BioMedical, Inc.
IBOStock
$0.46−31.34%52W
Market Cap$49.60M
P/E—
Div yield—
Beta-0.98
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.83%
Price vs S&P 500 (4W)-16.30%
VGM Score27.89
Market Capitalization$49.60M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IBOImpact BioMedical, Inc. | F | — | C | $0.46 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Impact BioMedical Inc develops therapeutics and preventative solutions targeting neurological, oncological, and immune-related diseases. The company also advances open-air defense technologies designed to reduce transmission of airborne infectious diseases, including tuberculosis and influenza. Its proprietary platforms include Linebacker, Laetose, 3F, and Equivir.